Health System

The opioid crisis continues to be one of the worst public health crises that the United States has ever seen.

Optimism is strong around the pharmacy industry as we head into a new decade, and many believe that 2020 is going to be a pivotal year for the industry.

Here are the top drugs expected to be approved this year.

NACDS says DIR fees, other policies need to change.

Individuals with a history of heart disease may be at an increased risk of developing kidney failure.

Overall cancer death rates declined by 29% over a 26-year time period, with the largest single-year drop on record reported from 2016 to 2017.

AstraZeneca’s supplemental New Drug Application for dapagliflozin (Farxiga) has been granted Priority Review by the FDA.

The critical role of distributors amid natural disasters, and strategies to protect and maintain the pharma supply chain

A new study examined diabetes as an independent predictor of heart failure. 

Olaparib (Lynparza, Merck and AstraZeneca) is approved for the maintenance treatment of adult patients with germline BRCA-mutated metastatic pancreatic cancer.

In 2020, we know there will be a renewed focus on collaborating across health care specialties while reducing costs.

Our most-read FDA approval articles from 2019. 

Ongoing threats to the safety of intravenous (IV) drug delivery include drug shortages and lack of IV product standardization, according to an expert panel.

Initiating conversation takes time and effort.

Invasive methods did not perform better than drug treatment in patients with stable ischemic heart disease

Fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo and AstraZeneca) is a new treatment option for patients with HER2-positive breast cancer who have progressed after 2 or more prior regimens.

The proposed rule would allow for the importation of certain drugs from Canada.

As 2019 draws to a close, let’s look back at some of the top pharmacy news stories of the year.

Pharmacists can play an integral role in transitions-of-care for patients with chronic obstructive pulmonary disease (COPD) to prevent hospital readmissions.

As participation in the 340B program becomes more of a political football especially in the upcoming 2020 election year, it is even more important to be mindful of access requirements and compliance tracking.

Every year, Drug Topics® asks pharmacists about their job experiences. These are the results from the 2019 annual pharmacy salary survey. 

20% subcutaneous immunoglobulin therapy.

Officials with the FDA have approved a new indication and label expansion for icosapent ethyl (Vascepa, Amarin).

As hospital and health systems experienced nearly 20% growth in the specialty drug market in 2018, health systems continue to establish their own specialty pharmacies or expand their existing capabilities.

A report issued this week at the 2019 American Society of Health System Pharmacists Midyear Clinical Meeting & Exposition from McKesson RxO detailed the major trends and challenges in health care ahead.